Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate

Rheumatology

Volumn 47, Issue 4, 2008, Pages 535-541

  Vera Llonch, M ^a   Massarotti, E ^b   Wolfe, F ^c   Shadick, N ^d   Westhovens, R ^e   Sofrygin, O ^a   Maclean, R ^f   Yuan, Y ^f   Oster, G ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abatacept; Cost effectiveness; Methotrexate; Outcomes; Rheumatoid arthritis

Indexed keywords

ABATACEPT; METHOTREXATE; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE SEVERITY; DRUG COST; DRUG RESPONSE; HEALTH CARE COST; HEALTH CARE UTILIZATION; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIMULATION; ADOLESCENT; ADULT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG ANTAGONISM; ECONOMICS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOCONJUGATES; MALE; METHOTREXATE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049180388     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken007     Document Type: Article

References (37)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
2. Olsen NJ, Stein MC. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
3. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
4. Combe B. Switching between anti-TNF α agents: What is the evidence? Joint Bone Spine 2004;71:169-71.
5. Pincus T, Yazici Y, van Vollenhoeven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for long term observations in standard care to complement clinical trials. J Rheumatol 2006;33:2372-5.
6. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med 2006;144:865-76.
8. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assessment Questionnaire, Disability and Pain scales. J Rheumatol 1982;9:789-93.
9. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) conceptual framework and item selection. Med Care 1992;30:473-84.
10. Kobelt G, Lindgren P, Singh A, Klareshog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-79.
11. Brennan A, Bansback N, Reynolds A, Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2003;42:1-13.
12. Kobelt G, Johnsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
13. Clark W, Jobanputra P, Barton P, Burls A. Technology assessment report commissioned by the HTA programme on behalf of the National Institute for Clinical Excellence: The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults. West Midlands Health Technology Assessment Collaboration (WMHTAC). Web publication, 2003. http://eprints.bham.ac.uk/32/1/Clark_W,_Anakinra.pdf
14. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
15. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation. Health Technol Assess 2002;6:1-110.
16. Halpern E, Weinstein M, Hunink M, Gazelle GS. Representing first- and secondorder uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-22.
17. Craig B, Black M, Sendi P. Uncertainty in decision models analyzing costeffectiveness. Med Decis Making 2000;20:135-7.
18. Kuntz K, Weinstein M. Modeling in economic evaluation. In: Drummond M, McGuire A, eds. Economic evaluation in health care: Merging theory with practice. New York: Oxford University Press, 2001;141-71.
19. Goldie S. Chapter 15: Public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monograph 2003;31:102-10.
20. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
21. Lipsky PE, van der Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343: 1594-602.
22. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
23. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
24. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004;63:494-7.
25. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: Evolving concepts. Arthritis Rheum 2001;44:1234-6.
26. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7.
27. US Bureau of the Census, Statistical Abstract of the United States: Washington, DC, 2004.
28. Dolan P. Modeling valuations for EuroQol Health States. Med Care 1997;35:1095-108.
29. Orencia® product label information. Princeton, NJ: Bristol-Myers Squibb., 2006.
30. US Department of Human Services (DHHS), National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Adult, Exam and Laboratory Data files (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention, 1996. Public Use Data File Documentation 762000. Available from the National Technical Information Service (NTIS), Springfield, VA.
31. Drug Topics® Red Book®. Montvale, NJ: Medical Economics Inc., 2006.
32. American Medical Association. Medicare RBRVS: The physician guide. Chicago, IL: American Medical Association, 2006.
33. US Bureau of Labor Statistics. Consumer price index. Washington DC: US Department of Labor, 2006.
34. Feller W. An introduction to probability theory and its applications (Vol. 1). 3rd edition. New York: John Wiley & Sons, 1968.
35. Weinstein MC, Siegel JE, Gold MR, Kamlet MS. Russell LB for the Panel on Cost-Effectiveness in Health and Medicine. Consensus statement. Recommendations of the panel on cost-effectiveness in health and medicine. J Am Med Assoc 1996;276:1253-8.
36. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002;47:655-61.
37. Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: Randomized controlled trials overestimate treatment response and effectiveness. Rheumatology 2005;44(Suppl. 4):iV18-22.